Startseite

Aktien

AlzeCure Pharma

Nachrichten

AlzeCure Pharma Aktie

Aktie

ISIN: SE0010133785 WKN: A2N951 SYM: AC6 Land Flagge SE

Schweden

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,1445

EUR

-4,30 %

-0,0065 EUR

Letzter Kurs 07.11.25 Frankfurt

AlzeCure Pharma Aktie kaufen

Geldkurs

07.11.25

0,1650

EUR

12.100 STK

Briefkurs

07.11.25

0,2210

EUR

13.600 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's 14.10.25 · Accesswire · AlzeCure Pharma
AlzeCure Pharma to Present at Redeye Neurology Day on October 15 07.10.25 · Accesswire · AlzeCure Pharma
Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 08.09.25 · Accesswire · AlzeCure Pharma
Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference 04.09.25 · Accesswire · AlzeCure Pharma
AlzeCure Publishes its Interim Report for January - June 2025 26.08.25 · Accesswire · AlzeCure Pharma
AlzeCure Appoints Cecilia Wadell as New Head of Development 20.08.25 · Accesswire · AlzeCure Pharma
AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs 19.08.25 · Accesswire · AlzeCure Pharma
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference 05.08.25 · Accesswire · AlzeCure Pharma
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain 29.07.25 · Accesswire · AlzeCure Pharma
AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option 24.07.25 · Accesswire · AlzeCure Pharma
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results 24.07.25 · Accesswire · AlzeCure Pharma
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results 23.07.25 · Accesswire · AlzeCure Pharma

1
2
3

Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against ... 124 Leser

AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million 192 Leser
New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's ... 164 Leser
New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment 160 Leser
Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain ... 140 Leser
AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference 136 Leser
AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the ... 136 Leser
Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference 136 Leser
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against ... 132 Leser
AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's ... 132 Leser
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results 128 Leser